EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

India’s Semaglutide Generic Boom Reshapes GLP-1 Market in 2026 - On March 20, 2026, Novo Nordisk’s patent on semaglutide expired in India, triggering one of the most significant transformations in the country’s pharmaceutical history. Within weeks, more than 40 Indian generic drugmakers launched approximately 50 branded generic versions of the active ingredient found in Ozempic® and Wegovy®, fundamentally reshaping access to GLP-1 receptor agonist therapies […]
CDSCO 2026 Overhaul: GMP Audits Outsourced, 1,500 Experts Hired as India Tightens Pharma Quality Standards - The Central Drugs Standard Control Organization (CDSCO) is undertaking its most significant regulatory transformation in decades. In a series of reforms announced in early 2026, India’s drug regulator has unveiled plans to outsource Good Manufacturing Practices (GMP) audits to certified third-party agencies, build a 1,500-strong scientific cadre, and ease export No Objection Certificate (NOC) norms […]
CDSCO 2026 Reforms: Prior Intimation, GMP Audits & Faster Drug Approvals - The Central Drugs Standard Control Organization (CDSCO), India’s national drug regulatory authority, has undertaken the most significant regulatory modernization in its history during the first half of 2026. From introducing a “prior intimation” system that replaces lengthy license applications to outsourcing GMP audits and building a 1,500-member scientific cadre, these reforms are reshaping how drugs […]
US 100% Pharma Tariff Spares Indian Generics — What Buyers and Exporters Need to Know - The United States imposed a sweeping 100% tariff on patented pharmaceutical imports on April 2, 2026, under Section 232 of the Trade Expansion Act. However, generic medicines — which make up approximately 90% of India’s pharma exports to the US — were explicitly exempted from the levy. This article breaks down what the new tariff […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us